Table 1.
Clinical characteristics of the patients with gastric cancer
| Variables | n = 83 |
|---|---|
| Age, median (range), years | 74 (43–89) |
| Sex | |
| Male | 53 |
| Female | 30 |
| Body mass index | 22.2 (10.9–33.3) |
| Peak expiratory flow rate, L/sec | 5.3 (1.4–9.5) |
| Time interval between zinc examination and surgery, median (range), days | 22 (3–64) |
| Tumor location of gastric cancer | |
| Upper third of the stomach | 16 |
| Middle third of the stomach | 32 |
| Lower third of the stomach | 29 |
| Entire | 6 |
| Macroscopic type of gastric cancer | |
| Type 0 | 36 |
| Type 1 | 6 |
| Type 2 | 21 |
| Type 3 | 13 |
| Type 4 | 7 |
| Pathology | |
| Intestinal type | 46 |
| Diffuse type | 37 |
| Disease stage | |
| I | 43 |
| II | 23 |
| III | 13 |
| IV | 4 |
| Serum H. pylori antibody | |
| Positive | 35 |
| Negative | 48 |
| Length of hospital stay, days | 15 (8–158) |
| Zinc level, μg/dL | 73 (20–152) |
| Neutrophil count, mm3 | 3,805 (1,450–9,380) |
| Lymphocyte count, mm3 | 1,600 (280–3,150) |
| Albumin, g/dL | 4.1 (1.4–5.2) |
| C-reactive protein, mg/dL | 0.12 (0.01–28.9) |
| Neutrophil-to-lymphocyte ratio | 2.37 (0.73–28.68) |